David Yi Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
David Yi Yang has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Camille Lupianez-Merly
Clinical Enteric Neuroscience and Translational Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota, USA
2 shared publications - Irene A. Busciglio
Clinical Enteric Neuroscience and Translational Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota, USA
2 shared publications - Michael Camilleri
Clinical Enteric Neuroscience Translational and Epidemiological Research, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota
2 shared publications - Michael Ryks
Clinical Enteric Neuroscience and Translational Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota, USA
2 shared publications - Andre Franke
Institute of Clinical Molecular Biology, Kiel University and University Hospital Schleswig-Holstein, Kiel, Germany
1 shared publication - Animesh Acharjee
Department of Cancer and Genomic Sciences, School of Medical Sciences, College of Medicine and Health University of Birmingham Birmingham UK
1 shared publication
Latest Publications
- Open Access
- 1 October 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (10)
Treatment of Refractory Gastroparesis With Laparoscopic Sleeve Gastrectomy and Pyloroplasty Leading to Symptom Improvement and Increased Gastric Emptying: First Clinical Experience in a Canadian Center
Laparoscopic sleeve gastrectomy (LSG) and pyloroplasty have been identified as treatment options for gastroparesis refractory to dietary, medical, gastric electrical stimulation, and advanced endoscopic therapies (ie, gastric peroral endoscopic myotomy). This case outlines the management of refractory idiopathic gastroparesis in a 62-year-old man who underwent LSG and pyloroplasty with successful improvements in patient-reported symptoms, gastric emptying rate, and weight gain. This is the first reported case of combined LSG and pyloroplasty being used to treat refractory gastroparesis in a Canadian center and adds to a growing body of evidence that LSG and pyloroplasty can be efficacious for refractory gastroparesis.
- 1 October 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (10)
Open AccessTreatment of Refractory Gastroparesis With Laparoscopic Sleeve Gastrectomy and Pyloroplasty Leading to Symptom Improvement and Increased Gastric Emptying: First Clinical Experience in a Canadian Center
Laparoscopic sleeve gastrectomy (LSG) and pyloroplasty have been identified as treatment options for gastroparesis refractory to dietary, medical, gastric electrical stimulation, and advanced endoscopic therapies (ie, gastric peroral endoscopic myotomy). This case outlines the management of refractory idiopathic gastroparesis in a 62-year-old man who underwent LSG and pyloroplasty with successful improvements in patient-reported symptoms, gastric emptying rate, and weight gain. This is the first reported case of combined LSG and pyloroplasty being used to treat refractory gastroparesis in a Canadian center and adds to a growing body of evidence that LSG and pyloroplasty can be efficacious for refractory gastroparesis.
- Open Access
- 28 October 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 17 (1) , e00944
Indomethacin Fails to Increase Intestinal Permeability in Healthy Volunteers
INTRODUCTION: Indomethacin is often used experimentally to induce intestinal hyperpermeability, enabling evaluation of interventions targeting barrier function. METHODS: We conducted a randomized, double-blind, placebo-controlled study (NCT05538247) in healthy volunteers to assess whether a supplement could mitigate indomethacin-induced hyperpermeability. Participants received 150 mg/d of indomethacin for 6 days, either before or during placebo/supplement administration. Permeability was measured using 13 C-mannitol and lactulose urinary excretion. RESULTS: Contrary to expectations, indomethacin failed to increase 13 C-mannitol excretion in either group. No meaningful elevations in serum (zonulin, claudins) or fecal (calprotectin) biomarkers were observed. DISCUSSION: Our findings suggest that the expected increase in intestinal permeability after indomethacin administration may not be consistently observed in healthy volunteers. These results highlight the need to carefully consider the reproducibility and sensitivity of this model in future clinical studies aiming to investigate gut barrier function.
- 28 October 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 17 (1) , e00944
Open AccessIndomethacin Fails to Increase Intestinal Permeability in Healthy Volunteers
INTRODUCTION: Indomethacin is often used experimentally to induce intestinal hyperpermeability, enabling evaluation of interventions targeting barrier function. METHODS: We conducted a randomized, double-blind, placebo-controlled study (NCT05538247) in healthy volunteers to assess whether a supplement could mitigate indomethacin-induced hyperpermeability. Participants received 150 mg/d of indomethacin for 6 days, either before or during placebo/supplement administration. Permeability was measured using 13 C-mannitol and lactulose urinary excretion. RESULTS: Contrary to expectations, indomethacin failed to increase 13 C-mannitol excretion in either group. No meaningful elevations in serum (zonulin, claudins) or fecal (calprotectin) biomarkers were observed. DISCUSSION: Our findings suggest that the expected increase in intestinal permeability after indomethacin administration may not be consistently observed in healthy volunteers. These results highlight the need to carefully consider the reproducibility and sensitivity of this model in future clinical studies aiming to investigate gut barrier function.
- Open Access
- 28 May 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 16 (7) , e00865
Effects of Ricinoleic Acid (Castor Oil) on Gut Permeability in Healthy Participants: Provocative Test for Treatments Aimed at Restoring Barrier Function
INTRODUCTION: Altered intestinal permeability (IP) is implicated in multiple gastrointestinal and systemic disease conditions; an experimental model of perturbed IP in healthy subjects is needed. Traditional approaches to perturbing IP include use of nonsteroidal anti-inflammatory drugs. METHODS: We conducted a single-center, randomized, placebo-controlled pilot study of dose-related effects of castor oil (CO) (and its ingredient ricinoleic acid) at 750, 1,500, or 3,000 mg daily doses on IP. Permeability was assessed using validated 13C-mannitol and lactulose urine excretion at 0–2, 8–24, and 0–24 hours after oral administration. RESULTS: Permeability analysis across all groups demonstrated significant difference among the groups for 0–2 hours 13C-mannitol, 0–24 hours 13C-mannitol, and borderline significant difference for 2–8 hours 13C-mannitol (P = 0.060) and 0–24 hours lactulose (P = 0.056). Direct comparison of 3,000 mg CO vs placebo (t test) demonstrated higher excretion of 13C-mannitol and lactulose at 0–2, and 0–24 hours, and lactulose at 2–8 hours. DISCUSSION: CO may perturb small intestinal and colonic permeability in healthy adults.
- 28 May 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 16 (7) , e00865
Open AccessEffects of Ricinoleic Acid (Castor Oil) on Gut Permeability in Healthy Participants: Provocative Test for Treatments Aimed at Restoring Barrier Function
INTRODUCTION: Altered intestinal permeability (IP) is implicated in multiple gastrointestinal and systemic disease conditions; an experimental model of perturbed IP in healthy subjects is needed. Traditional approaches to perturbing IP include use of nonsteroidal anti-inflammatory drugs. METHODS: We conducted a single-center, randomized, placebo-controlled pilot study of dose-related effects of castor oil (CO) (and its ingredient ricinoleic acid) at 750, 1,500, or 3,000 mg daily doses on IP. Permeability was assessed using validated 13C-mannitol and lactulose urine excretion at 0–2, 8–24, and 0–24 hours after oral administration. RESULTS: Permeability analysis across all groups demonstrated significant difference among the groups for 0–2 hours 13C-mannitol, 0–24 hours 13C-mannitol, and borderline significant difference for 2–8 hours 13C-mannitol (P = 0.060) and 0–24 hours lactulose (P = 0.056). Direct comparison of 3,000 mg CO vs placebo (t test) demonstrated higher excretion of 13C-mannitol and lactulose at 0–2, and 0–24 hours, and lactulose at 2–8 hours. DISCUSSION: CO may perturb small intestinal and colonic permeability in healthy adults.
- Open Access
A Multi-Factorial Observational Study on Sequential Fecal Microbiota Transplant in Patients with Medically Refractory Clostridioides difficile Infection
Fecal microbiota transplantation (FMT) is highly effective in recurrent Clostridioides difficile infection (CDI); increasing evidence supports FMT in severe or fulminant Clostridioides difficile infection (SFCDI). However, the multifactorial mechanisms that underpin the efficacy of FMT are not fully understood. Systems biology approaches using high-throughput technologies may help with mechanistic dissection of host-microbial interactions. Here, we have undertaken a deep phenomics study on four adults receiving sequential FMT for SFCDI, in which we performed a longitudinal, integrative analysis of multiple host factors and intestinal microbiome changes. Stool samples were profiled for changes in gut microbiota and metabolites and blood samples for alterations in targeted epigenomic, metabonomic, glycomic, immune proteomic, immunophenotyping, immune functional assays, and T-cell receptor (TCR) repertoires, respectively. We characterised temporal trajectories in gut microbial and host immunometabolic data sets in three responders and one non-responder to sequential FMT. A total of 562 features were used for analysis, of which 78 features were identified, which differed between the responders and the non-responder. The observed dynamic phenotypic changes may potentially suggest immunosenescent signals in the non-responder and may help to underpin the mechanisms accompanying successful FMT, although our study is limited by a small sample size and significant heterogeneity in patient baseline characteristics. Our multi-omics integrative longitudinal analytical approach extends the knowledge regarding mechanisms of efficacy of FMT and highlights preliminary novel signatures, which should be validated in larger studies.
Open AccessA Multi-Factorial Observational Study on Sequential Fecal Microbiota Transplant in Patients with Medically Refractory Clostridioides difficile Infection
Fecal microbiota transplantation (FMT) is highly effective in recurrent Clostridioides difficile infection (CDI); increasing evidence supports FMT in severe or fulminant Clostridioides difficile infection (SFCDI). However, the multifactorial mechanisms that underpin the efficacy of FMT are not fully understood. Systems biology approaches using high-throughput technologies may help with mechanistic dissection of host-microbial interactions. Here, we have undertaken a deep phenomics study on four adults receiving sequential FMT for SFCDI, in which we performed a longitudinal, integrative analysis of multiple host factors and intestinal microbiome changes. Stool samples were profiled for changes in gut microbiota and metabolites and blood samples for alterations in targeted epigenomic, metabonomic, glycomic, immune proteomic, immunophenotyping, immune functional assays, and T-cell receptor (TCR) repertoires, respectively. We characterised temporal trajectories in gut microbial and host immunometabolic data sets in three responders and one non-responder to sequential FMT. A total of 562 features were used for analysis, of which 78 features were identified, which differed between the responders and the non-responder. The observed dynamic phenotypic changes may potentially suggest immunosenescent signals in the non-responder and may help to underpin the mechanisms accompanying successful FMT, although our study is limited by a small sample size and significant heterogeneity in patient baseline characteristics. Our multi-omics integrative longitudinal analytical approach extends the knowledge regarding mechanisms of efficacy of FMT and highlights preliminary novel signatures, which should be validated in larger studies.
- 9 July 2018
- Published by Elsevier in Digestive and Liver Disease
- Vol. 50 (12) , 1367
Aortoenteric fistula: A rare cause of upper gastrointestinal bleed captured on endoscopy with exceptional clarity
- 9 July 2018
- Published by Elsevier in Digestive and Liver Disease
- Vol. 50 (12) , 1367
Aortoenteric fistula: A rare cause of upper gastrointestinal bleed captured on endoscopy with exceptional clarity